Initial preclinical safety of non-replicating human endogenous retrovirus envelope protein-coated baculovirus vector-based vaccines against human papillomavirus

Su Eun Han, Mi Gyeong Kim, Soondong Lee, Hee Jeong Cho, Youngro Byun, Sujeong Kim, Young Bong Kim, Yongseok Choi, Yu Kyoung Oh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Human endogenous retrovirus (HERV) envelope protein-coated, baculovirus vector-based HPV 16L1 (AcHERV-HPV16L1) is a non-replicating recombinant baculoviral vaccine. Here, we report an initial evaluation of the preclinical safety of AcHERV-HPV16L1 vaccine. In an acute toxicity study, a single administration of AcHERV-HPV16L1 DNA vaccine given intramuscularly (i.m.) to mice at a dose of 1×108 plaque-forming units (PFU) did not cause significant changes in body weight compared with vehicle-treated controls. It did cause a brief increase in the weights of some organs on day 15 post-treatment, but by day 30, all organ weights were not significantly different from those in the vehicle-treated control group. No hematological changes were observed on day 30 post-treatment. In a range-finding toxicity study with three doses of 1×107, 2×107 and 5×107 PFU once daily for 5days, the group treated with 5×107 PFU showed a transient decrease in the body weights from day 5 to day 15 post-treatment, but recovery to the levels similar to those in the vehicle-treated control group by post-treatment day 20. Organ weights were slightly higher for lymph nodes, spleen, thymus and liver after repeated dosing with 5×107 PFU on day 15, but had normalized by day 30. Moreover, repeated administration of AcHERV-HPV16L1 did not induce myosin-specific autoantibody in serum, and did not cause immune complex deposition or tissue damage at injection sites. Taken together, these results provide preliminary evidence of the preclinical safety of AcHERV-based HPV16L1 DNA vaccines in mice.

Original languageEnglish
Pages (from-to)1474-1483
Number of pages10
JournalJournal of Applied Toxicology
Volume33
Issue number12
DOIs
Publication statusPublished - 2013 Dec 1

Fingerprint

Retroviridae Proteins
Endogenous Retroviruses
Papillomavirus Vaccines
Baculoviridae
Organ Size
Vaccines
Safety
DNA Vaccines
Toxicity
Proteins
Thymus
Control Groups
Synthetic Vaccines
Body Weight Changes
Therapeutics
Myosins
Antigen-Antibody Complex
Liver
Autoantibodies
Thymus Gland

Keywords

  • Acute toxicity
  • Baculoviral vector
  • DNA vaccine
  • Human papillomavirus
  • Sub-chronic toxicity

ASJC Scopus subject areas

  • Toxicology

Cite this

Initial preclinical safety of non-replicating human endogenous retrovirus envelope protein-coated baculovirus vector-based vaccines against human papillomavirus. / Han, Su Eun; Kim, Mi Gyeong; Lee, Soondong; Cho, Hee Jeong; Byun, Youngro; Kim, Sujeong; Kim, Young Bong; Choi, Yongseok; Oh, Yu Kyoung.

In: Journal of Applied Toxicology, Vol. 33, No. 12, 01.12.2013, p. 1474-1483.

Research output: Contribution to journalArticle

Han, Su Eun ; Kim, Mi Gyeong ; Lee, Soondong ; Cho, Hee Jeong ; Byun, Youngro ; Kim, Sujeong ; Kim, Young Bong ; Choi, Yongseok ; Oh, Yu Kyoung. / Initial preclinical safety of non-replicating human endogenous retrovirus envelope protein-coated baculovirus vector-based vaccines against human papillomavirus. In: Journal of Applied Toxicology. 2013 ; Vol. 33, No. 12. pp. 1474-1483.
@article{85252c2a796e40ab844d489566e98e4b,
title = "Initial preclinical safety of non-replicating human endogenous retrovirus envelope protein-coated baculovirus vector-based vaccines against human papillomavirus",
abstract = "Human endogenous retrovirus (HERV) envelope protein-coated, baculovirus vector-based HPV 16L1 (AcHERV-HPV16L1) is a non-replicating recombinant baculoviral vaccine. Here, we report an initial evaluation of the preclinical safety of AcHERV-HPV16L1 vaccine. In an acute toxicity study, a single administration of AcHERV-HPV16L1 DNA vaccine given intramuscularly (i.m.) to mice at a dose of 1×108 plaque-forming units (PFU) did not cause significant changes in body weight compared with vehicle-treated controls. It did cause a brief increase in the weights of some organs on day 15 post-treatment, but by day 30, all organ weights were not significantly different from those in the vehicle-treated control group. No hematological changes were observed on day 30 post-treatment. In a range-finding toxicity study with three doses of 1×107, 2×107 and 5×107 PFU once daily for 5days, the group treated with 5×107 PFU showed a transient decrease in the body weights from day 5 to day 15 post-treatment, but recovery to the levels similar to those in the vehicle-treated control group by post-treatment day 20. Organ weights were slightly higher for lymph nodes, spleen, thymus and liver after repeated dosing with 5×107 PFU on day 15, but had normalized by day 30. Moreover, repeated administration of AcHERV-HPV16L1 did not induce myosin-specific autoantibody in serum, and did not cause immune complex deposition or tissue damage at injection sites. Taken together, these results provide preliminary evidence of the preclinical safety of AcHERV-based HPV16L1 DNA vaccines in mice.",
keywords = "Acute toxicity, Baculoviral vector, DNA vaccine, Human papillomavirus, Sub-chronic toxicity",
author = "Han, {Su Eun} and Kim, {Mi Gyeong} and Soondong Lee and Cho, {Hee Jeong} and Youngro Byun and Sujeong Kim and Kim, {Young Bong} and Yongseok Choi and Oh, {Yu Kyoung}",
year = "2013",
month = "12",
day = "1",
doi = "10.1002/jat.2815",
language = "English",
volume = "33",
pages = "1474--1483",
journal = "Journal of Applied Toxicology",
issn = "0260-437X",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - Initial preclinical safety of non-replicating human endogenous retrovirus envelope protein-coated baculovirus vector-based vaccines against human papillomavirus

AU - Han, Su Eun

AU - Kim, Mi Gyeong

AU - Lee, Soondong

AU - Cho, Hee Jeong

AU - Byun, Youngro

AU - Kim, Sujeong

AU - Kim, Young Bong

AU - Choi, Yongseok

AU - Oh, Yu Kyoung

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Human endogenous retrovirus (HERV) envelope protein-coated, baculovirus vector-based HPV 16L1 (AcHERV-HPV16L1) is a non-replicating recombinant baculoviral vaccine. Here, we report an initial evaluation of the preclinical safety of AcHERV-HPV16L1 vaccine. In an acute toxicity study, a single administration of AcHERV-HPV16L1 DNA vaccine given intramuscularly (i.m.) to mice at a dose of 1×108 plaque-forming units (PFU) did not cause significant changes in body weight compared with vehicle-treated controls. It did cause a brief increase in the weights of some organs on day 15 post-treatment, but by day 30, all organ weights were not significantly different from those in the vehicle-treated control group. No hematological changes were observed on day 30 post-treatment. In a range-finding toxicity study with three doses of 1×107, 2×107 and 5×107 PFU once daily for 5days, the group treated with 5×107 PFU showed a transient decrease in the body weights from day 5 to day 15 post-treatment, but recovery to the levels similar to those in the vehicle-treated control group by post-treatment day 20. Organ weights were slightly higher for lymph nodes, spleen, thymus and liver after repeated dosing with 5×107 PFU on day 15, but had normalized by day 30. Moreover, repeated administration of AcHERV-HPV16L1 did not induce myosin-specific autoantibody in serum, and did not cause immune complex deposition or tissue damage at injection sites. Taken together, these results provide preliminary evidence of the preclinical safety of AcHERV-based HPV16L1 DNA vaccines in mice.

AB - Human endogenous retrovirus (HERV) envelope protein-coated, baculovirus vector-based HPV 16L1 (AcHERV-HPV16L1) is a non-replicating recombinant baculoviral vaccine. Here, we report an initial evaluation of the preclinical safety of AcHERV-HPV16L1 vaccine. In an acute toxicity study, a single administration of AcHERV-HPV16L1 DNA vaccine given intramuscularly (i.m.) to mice at a dose of 1×108 plaque-forming units (PFU) did not cause significant changes in body weight compared with vehicle-treated controls. It did cause a brief increase in the weights of some organs on day 15 post-treatment, but by day 30, all organ weights were not significantly different from those in the vehicle-treated control group. No hematological changes were observed on day 30 post-treatment. In a range-finding toxicity study with three doses of 1×107, 2×107 and 5×107 PFU once daily for 5days, the group treated with 5×107 PFU showed a transient decrease in the body weights from day 5 to day 15 post-treatment, but recovery to the levels similar to those in the vehicle-treated control group by post-treatment day 20. Organ weights were slightly higher for lymph nodes, spleen, thymus and liver after repeated dosing with 5×107 PFU on day 15, but had normalized by day 30. Moreover, repeated administration of AcHERV-HPV16L1 did not induce myosin-specific autoantibody in serum, and did not cause immune complex deposition or tissue damage at injection sites. Taken together, these results provide preliminary evidence of the preclinical safety of AcHERV-based HPV16L1 DNA vaccines in mice.

KW - Acute toxicity

KW - Baculoviral vector

KW - DNA vaccine

KW - Human papillomavirus

KW - Sub-chronic toxicity

UR - http://www.scopus.com/inward/record.url?scp=84886098316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886098316&partnerID=8YFLogxK

U2 - 10.1002/jat.2815

DO - 10.1002/jat.2815

M3 - Article

C2 - 22987290

AN - SCOPUS:84886098316

VL - 33

SP - 1474

EP - 1483

JO - Journal of Applied Toxicology

JF - Journal of Applied Toxicology

SN - 0260-437X

IS - 12

ER -